2nd RSC Symposium on Chemical Biology for Drug Discovery

2nd RSC Symposium on

Chemical Biology

for Drug Discovery

Tuesday - Wednesday, 20^th-21^st March 2012

at AstraZeneca, Alderley Park, Macclesfield, UK

Click image to the left for flier download.

Downloads

Final announcement (print-friendly 1.2 mb)

RSC website

Introduction
This symposium covered progress in the interdisciplinary field of Chemical Biology in enhancing our understanding of the molecular mechanisms of human biology in health and disease.

Topics included discovery and use of chemical probes, chemical modification of biological molecules, in-cell protein labelling, carbohydrate therapeutics and biomarkers, and the study of protein-protein interactions.
Who attended
This meeting was aimed at chemists and biologists from across the academic and industrial sectors interested in harnessing chemical science to answer fundamental questions in biology.

Programme - speaker presentations

Where speaker names are shown thus, they are linked to the .pdf presentation.

Programme - Tuesday 20th March 2012

09:00 Registration

10:00 Welcome and opening remarks

Tom Heightman, Director of Medicinal Chemistry, Astex Pharmaceuticals

Menelas Pangalos, EVP Innovative Medicines, AstraZeneca

10:15 Development of bisubstrate-based protein kinase inhibitors and monitoring of

phosphatase activity using dynamic peptide microarrays

Rob Liskamp, Utrecht University

11:00 Chemical handles on posttranslational modifications: enabling tools for drug discovery

Ed Tate, Imperial College London

11:45 Manipulating maleimides: new opportunities in protein modification

James Baker, University College London

12:30 Lunch

13:30 Inhibition of protein-protein interactions using designed molecules

Andrew Wilson, Leeds University

14:15 Synthesis directed at the disruption of protein-protein interactions - asthma- and cancer-

related targets

Alan Spivey, Imperial College London

15:00 Synthetic approaches for the systematic exploration of biologically-relevant chemical

space

Adam Nelson, Leeds University

15:45 Refreshments

16:15 The GSK published kinase inhibitor set: a resource for investigating the untargeted

kinome

Bill Zuercher, GlaxoSmithKline

17:00 A chemical approach to controlling cell fate

Sheng Ding, Scripps

17:45 Poster session and drinks reception

19:30 Conference dinner at Players Restaurant, Hale

Programme - Wednesday 21st March 2012

09:00 Chemical biology of glucosylceramide metabolism in health and disease

Herman Overkleeft, Leiden University

09:45 Enzymatic reactions on arrays surfaces

Sabine Flitsch, University of Manchester

10:30 Refreshments

11:00 Sugars and proteins

Ben Davis, Oxford University

11:45 Iminosugar drug discovery

Richard Storer, Summit

12:30 Lunch

13:30 PI3K gamma, probes and proteomics

Nigel Ramsden, Cellzome

14:15 Chemical probes for epigenetics

Mark Bunnage, Pfizer

15:00 Refreshments

15:30 Chemogenomic approaches to novel antimalarials

Ralph Mazitschek, Harvard University

16:15 Small molecule epigenetic intervention of disease

Matt Fuchter, Imperial College London

17:00 Closing remarks

Organising Committee

Paul Brennan                  The Structural Genomics Consortium
Frederick Goldberg         AstraZeneca
Tom Heightman (chair)    Astex Therapeutics
Lyn Jones                       Pfizer
Jason Micklefield            University of Manchester
Brandon Turunen             GlaxoSmithKline
Simon Ward                    University of Sussex

Acknowledgements / Sponsors

Special thanks to AstraZeneca who will be hosting this event. We are also grateful to our financial sponsors: Pfizer, GlaxoSmithKline, Lilly, Peakdale Molecular, and RSC-CBID (Chemical Biology Interface Division)